Oncology

Immatics has founded a US subsidiary

Immatics GmbH founds $60m US T-cell spin-out

By Fiona BARRY

German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.